You are here

Study Evaluating Piperacillin/Tazobactam in Complicated Urinary Infections.

Last updated on October 20, 2019

FOR MORE INFORMATION
Study Location
Antequera (Málaga), , Spain
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Urinary Infections
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
16 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Hospitalized patients over 16 years of age with complicated urinary infection produced
by bacteria that are suspected to be susceptible to treatment with
Piperacillin-tazobactam.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients known, or thought to be hypersensitivity to beta-lactams

- Patients with an uncomplicated urinary tract infection

NCT00195286
Pfizer
Completed
Study Evaluating Piperacillin/Tazobactam in Complicated Urinary Infections.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Descriptive Information
Brief TitleStudy Evaluating Piperacillin/Tazobactam in Complicated Urinary Infections.
Official TitleStudy of the Safety and Efficacy of Piperacillin/Tazobactam in the Treatment of Patients With Complicated Urinary Infections.
Brief SummaryThe primary objective is to study the efficacy of piperacillin/tazobactam in patients with complicated urinary tract infections
Detailed DescriptionNot Provided
Study TypeObservational
Study DesignObservational Model: Case-Only
Time Perspective: Prospective
Target Follow-Up DurationNot Provided
BiospecimenNot Provided
Sampling MethodNon-Probability Sample
Study PopulationPatients treated at internal medicine units
ConditionUrinary Infections
InterventionDrug: piperacillin/tazobactam
Study Groups/CohortsNot Provided
Publications *Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment StatusCompleted
Actual Enrollment
 (submitted: September 24, 2009)
180
Original Enrollment
 (submitted: September 12, 2005)
300
Actual Study Completion DateJuly 2007
Actual Primary Completion DateJuly 2007   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Hospitalized patients over 16 years of age with complicated urinary infection produced by bacteria that are suspected to be susceptible to treatment with Piperacillin-tazobactam.

Exclusion Criteria:

  • Patients known, or thought to be hypersensitivity to beta-lactams
  • Patients with an uncomplicated urinary tract infection
Sex/Gender
Sexes Eligible for Study:All
Ages16 Years and older   (Child, Adult, Older Adult)
Accepts Healthy VolunteersNo
ContactsContact information is only displayed when the study is recruiting subjects
Listed Location CountriesSpain
Removed Location Countries  
 
Administrative Information
NCT NumberNCT00195286
Other Study ID Numbers101315
Has Data Monitoring CommitteeNot Provided
U.S. FDA-regulated ProductNot Provided
IPD Sharing StatementNot Provided
Responsible PartyWyeth (Registry Contact: Clinical Trial Registry Specialist), Wyeth
Study SponsorWyeth is now a wholly owned subsidiary of Pfizer
CollaboratorsNot Provided
Investigators
Study Director:Medical MonitorWyeth is now a wholly owned subsidiary of Pfizer
PRS AccountWyeth is now a wholly owned subsidiary of Pfizer
Verification DateSeptember 2009

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now